The 2021 Japanese Gastric Cancer Association (JGCA) Treatment Guidelines recommend that T-DXd should be prioritised as a third-line therapy for patients with HER2-positive gastric cancer, as it is the only treatment for which survival prolongation was confirmed in comparison with chemotherapy regimens [13]. This evidence concerns the gene ERBB2 and gastric cancer.